Janssen-Cilag, a Johnson & Johnson company, has announced results from a matching-adjusted indirect comparison presented at this year’s European Hematology Association Congress in Milan, Italy. It suggested that fixed-duration ibrutinib plus venetoclax (I+V) is more effective than acalabrutinib plus venetoclax (A+V) in previously untreated chronic lymphocytic leukaemia (CLL), a slow-growing blood cancer of the white […]
The post Johnson & Johnson presents promising data on leukaemia treatment appeared first on Pharmafile.
